These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1450 related items for PubMed ID: 23922182

  • 21. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
    Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY.
    J Am Coll Cardiol; 2013 Jun 04; 61(22):2264-73. PubMed ID: 23562920
    [Abstract] [Full Text] [Related]

  • 22. Dabigatran for stroke prevention in all patients with atrial fibrillation?
    Hunchuck JE, Lake JD.
    Pharmacotherapy; 2011 Aug 04; 31(8):725-8. PubMed ID: 21923597
    [No Abstract] [Full Text] [Related]

  • 23. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S.
    J Am Coll Cardiol; 2013 Sep 03; 62(10):900-8. PubMed ID: 23770182
    [Abstract] [Full Text] [Related]

  • 24. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjøth F, Rosenzweig M, Lip GY.
    Am J Med; 2014 Jul 03; 127(7):650-656.e5. PubMed ID: 24530792
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI, Peacock WF, Bunz TJ, Alberts MJ.
    Stroke; 2017 Aug 03; 48(8):2142-2149. PubMed ID: 28655814
    [Abstract] [Full Text] [Related]

  • 29. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP, Halperin JL.
    Hosp Pract (1995); 2013 Feb 03; 41(1):37-48. PubMed ID: 23466966
    [Abstract] [Full Text] [Related]

  • 30. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S.
    Circulation; 2011 May 31; 123(21):2363-72. PubMed ID: 21576658
    [Abstract] [Full Text] [Related]

  • 31. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB, Sørensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, Køber L, Gislason GH, Torp-Pedersen C, Fosbøl EL.
    Europace; 2015 Feb 31; 17(2):187-93. PubMed ID: 25236181
    [Abstract] [Full Text] [Related]

  • 32. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M.
    Clin Ther; 2013 Jul 31; 35(7):967-984.e2. PubMed ID: 23870607
    [Abstract] [Full Text] [Related]

  • 33. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
    Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW.
    Circulation; 2015 Mar 17; 131(11):972-9. PubMed ID: 25595139
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H, Johnston SC, Easton JD, Kim AS.
    Stroke; 2012 Mar 17; 43(3):881-3. PubMed ID: 22308255
    [Abstract] [Full Text] [Related]

  • 35. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
    Korenstra J, Wijtvliet EP, Veeger NJ, Geluk CA, Bartels GL, Posma JL, Piersma-Wichers M, Van Gelder IC, Rienstra M, Tieleman RG.
    Europace; 2016 Sep 17; 18(9):1319-27. PubMed ID: 26843571
    [Abstract] [Full Text] [Related]

  • 36. Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S.
    Circulation; 2013 Nov 19; 128(21):2325-32. PubMed ID: 24081972
    [Abstract] [Full Text] [Related]

  • 37. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis.
    Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB.
    Circ Cardiovasc Qual Outcomes; 2016 Mar 19; 9(2):126-34. PubMed ID: 26812933
    [Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Shah SV, Gage BF.
    Circulation; 2011 Jun 07; 123(22):2562-70. PubMed ID: 21606397
    [Abstract] [Full Text] [Related]

  • 39. Dabigatran: will it change clinical practice?
    Wartak SA, Bartholomew JR.
    Cleve Clin J Med; 2011 Oct 07; 78(10):657-64. PubMed ID: 21968472
    [Abstract] [Full Text] [Related]

  • 40. New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
    Barrios V, Escobar C.
    Expert Opin Pharmacother; 2012 Dec 07; 13(18):2649-61. PubMed ID: 23167273
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 73.